Kanagawa, Japan, 29, May 2022 – FIMECS, Inc. (“FIMECS”) a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Sho Sawada has been appointed as new Board of Directors and CFO. Also, Yoshiyuki Jojima and Yoichi Yamagishi have been appointed as new Audit & Supervisory Board Member.
“We are excited to welcome new members and has been organized Audit & Supervisory Board to strengthen our corporate governance” said Yusuke Tominari, Ph.D., Co-Founder & CEO of FIMECS “We look forward to working with new members to accelerate the research in the targeted protein degradation field, and will contribute to deliver life-saving medicines to patients around the world.”
About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects.
# # #
FIMECS, Inc. Media Contact:
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
TEL: +81-466-96-0261
E-mail: info@fimecs.com